HALOZYME THERAPEUTICS, INC. Debt Instrument, Face Amount
HALOZYME THERAPEUTICS, INC. (HALO) had Debt Instrument, Face Amount of $2.18 billion as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFaceAmount · last filed 2026-02-17
- 2025-12-31: Debt Instrument, Face Amount $2.18B.
- 2025-09-30: Debt Instrument, Face Amount $1.52B.
- 2025-06-30: Debt Instrument, Face Amount $1.52B.
- 2025-03-31: Debt Instrument, Face Amount $1.52B.
| Period end | Debt Instrument, Face Amount |
|---|---|
| 2025-12-31 | $2.18B 10-K · filed 2026-02-17 |
| 2025-09-30 | $1.52B 10-Q · filed 2025-11-03 |
| 2025-06-30 | $1.52B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.52B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.52B 10-K · filed 2026-02-17 |
| 2024-09-30 | $1.52B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.52B 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.52B 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.52B 10-K · filed 2025-02-18 |
| 2023-09-30 | $1.52B 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.52B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.52B 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.54B 10-K · filed 2024-02-20 |
| 2022-09-30 | $1.54B 10-Q · filed 2022-11-08 |
| 2022-06-30 | $895.94M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $895.94M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $895.94M 10-K · filed 2023-02-21 |
| 2021-09-30 | $895.94M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $895.94M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $895.94M 10-Q · filed 2021-05-10 |
| 2021-01-01 | $460.00M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |